Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.

Going beyond breakthroughs

We understand that psychedelics are powerful medicines, but not magic pills. We understand that they can profoundly change lives, families, and communities, and that success requires more than just a breakthrough experience—it also takes careful, sensitive attention to every individual’s story, mindful preparation, and a grounded, realistic plan for what comes after.

Multidisciplinary expertise with human-centred care

Numinus boasts a diverse and interdisciplinary team of professionals, from physicians and psychiatrists to mindfulness teachers, nurses and psychotherapists, researchers and technicians. Our protocols are backed by rigorous science, and delivered by a team that understands that even the best tools still require genuine human care to be effective.

Curiosity and humility

At the core of what we do at Numinus is a deep sense of curiosity and humility about everything we encounter. We know that psychedelics, mindfulness, and embodied practices are not new tools, but rather owe a debt to some very old ways of being and caring for one another. We’re working every day to honour that wisdom and those traditions, and integrating it with the best that modern science has to offer.


View All Members


Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Cliquez ici pour la version française Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds VANCOUVER (March 4, 2021) – Numinus […]
March 4, 2021
FR: Numinus et Syreon fournissent une mise à jour concernant les essais cliniques à accès compassionnel sur la psilocybine
Des progrès significatifs ont été réalisés, alors que l’étude PRIME, parrainée par Numinus, sur la psychothérapie assistée par psilocybine pour les troubles liés à la consommation d’opiacés, de stimulants et/ou […]
March 2, 2021
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update
Cliquez ici pour la version française Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage VANCOUVER (March 2, 2021) […]
March 2, 2021
1 11 12 13 14 15 36
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram